Cargando…
Novel therapies in thrombotic thrombocytopenic purpura
ESSENTIALS: The standard of care for patients with TTP remains daily plasma exchange in addition to immune suppressive therapy. Despite the improved treatment options for TTP, the acute mortality of TTP remains between 15‐20%. Caplacizumab reduces the time to platelet recovery and the exacerbation r...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055500/ https://www.ncbi.nlm.nih.gov/pubmed/30046703 http://dx.doi.org/10.1002/rth2.12066 |